Sanofi-Aventis’ Rimonabant Cuts Visceral Fat
This article was originally published in The Pink Sheet Daily
ADAGIO-LIPIDS trial shows HDL cholesterol boost but not LDL.
You may also be interested in...
Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.
Sanofi-Aventis’ rimonabant is currently “approvable” at FDA for obesity.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.